Logo Kérwá
 

High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern

Loading...
Thumbnail Image

Date

Authors

Moreira Soto, Andrés
Gutiérrez, José María
Alape Girón, Alberto
Drexler, Jan Felix
Arguedas Gómez, Mauricio
Brenes Porras, Hebleen
Buján Boza, Willem Aart
Corrales Aguilar, Eugenia
Díaz Oreiro, Cecilia
Echeverri McCandless, Ann

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.

Description

Keywords

Equine antibodies, SARS-CoV-2, Therapy, Variant of concern, PRNT titers 50, Neutralization test, COVID-19, VIROLOGÍA

Citation

https://www.frontiersin.org/articles/10.3389/fmed.2021.735853/full

Collections

Endorsement

Review

Supplemented By

Referenced By